A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids.
Phase of Trial: Phase III
Latest Information Update: 08 Jul 2019
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 10 Sep 2018 This trial has been discontinued in UK-MHRA (End date : 2018-03-05)
- 31 Aug 2018 Biomarkers information updated
- 11 Jun 2018 Status changed from active, no longer recruiting to completed.